Defective Expression and DNA Variants of TGFBR2 in Chinese Small Cell Lung Carcinoma

ZhenHong Zhao,Jibin Xu,Jun Xie,Yang Bao,Xiaotian Wang,Lei Wang,Junjie Wu,Li Jin,Zhiyun Xu,Jiucun Wang

DOI: https://doi.org/10.5772/26780

2012-01-01

Abstract:IntroductionLung cancer is one of the most commonly diagnosed malignant tumors, and has the highest death rate of all cancer types.Both the incidence rate and death rate of lung cancer have increased rapidly worldwide during the last 50 years.Lung cancer has now become the leading cause of cancer death in males, and the second most common cause of cancer death in females, after breast cancer.According to data provided by the International Agency for Research on Cancer, about 1.6 million new lung cancer patients were confirmed in 2008, accounting for 13% of the total cancer cases, while about 1.4 million patients died, amounting to 18% of the total deaths caused by cancer worldwide (Jemal et al., 2011).Lung cancer can be divided according to histological subtype into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), with the latter accounting for about 14% of new lung cancer cases in the USA and Europe in 2004 (Jemal et al., 2004).The clinical and histological features of SCLC were first recognized by Barnard in 1926 as being distinct from those of other types of lung cancer (Barnard, 1926).SCLC cells develop from lung Kulchitsky cells, and SCLC can be further subdivided into three different types: oat-cell type, intermediate-cell type and mixed-cell type (Travis, 1999).Smoking is the key risk factor for SCLC, and more than 95% of patients develop SCLC as a result of tobacco smoking.Smoking more cigarettes and prolonging the duration of smoking can both increase the risk of developing SCLC (Brownson et al., 1992), while stopping smoking reduces its risk, compared to persistent smokers (Khuder and Mutgi, 2001;Jackman and Johnson, 2005).SCLC is very aggressive and the median survival time without treatment is less than 4 months.Chemotherapy and radiotherapy represent the two major treatments for SCLC.According to the standards developed by the Veterans Administration Lung Cancer Study Group, SCLC can be divided into two stages: a limited stage and an extensive stage (Simon, 2003).Cancer cells in limited-stage SCLC are restricted to the ipsilateral hemithorax